Market Overview

Microbiome Therapeutics and Diagnostics Report, 2018 Edition: Pipeline Analysis and Market Outlook to 2027 -


The "Microbiome
Therapeutics and Diagnostics, 2nd Edition: Pipeline Analysis and Market
report has been added to's

From microbes playing a role in our health, the discovery that microbes
destroyed the Mayan civilization, to the potential of microbes aiding
future interplanetary space exploration, the power of microbes is
immense. Since the Human Microbiome Project began, driven by a surge in
Next Generation Sequencing (NGS) tools; the human microbiome is drawing
interest from Big Pharma, Startups and academia to revolutionize health
and disease.

The race is now on to create innovative human microbiome products.
However, human microbiome R&D presents numerous challenges.
Collaboration is paramount for stakeholders to overcome unique
scientific and technology hurdles, manufacturing and regulation
challenges, intellectual property barriers and key ethical and social
issues, to maximize successful opportunities in this potentially
lucrative market.

Several key leading pipeline products will pave the way forward for the
future human microbiome market. In 2019, the first biotherapeutics could
hit the market with the arrival of Seres Therapeutics/ Nestl Health
Science's SER-109 and Rebiotix RBX2660, both for prevention of recurrent
C. difficile infection. In 2020, the market could witness the arrival of
the first human microbiome diagnostic product, Metabiomics' Colon Polyp
and Colon Cancer Test.

Key Topics Covered:

1 Executive Summary

2 Introduction To The Human Microbiome

3 Target Diseases Of Human Microbiome R&D

4 Scientific & Technology Strategies Driving Human Microbiome R&D

5 Major Challenges Of Human Microbiome R&D

6 Business Models Of Key Human Microbiome Players

7 The Human Microbiome Biotherapeutics Pipeline: Key Clinical Candidates

8 The Human Microbiome Diagnostics Pipeline: Key Products In Development

9 The Future Market For Human Microbiome Biotherapeutics & Diagnostics

10 Bibliography

Companies Mentioned

  • AO Biome LLC
  • Assembly Biosciences
  • C3J Therapeutics Inc.
  • Enterome Biosciences S.A.
  • Finch Therapeutics
  • Metabiomics
  • Metabogen AB
  • Microbiome Therapeutics LLC
  • Osel Inc.
  • Rebiotix Inc.
  • Ritter Pharmaceuticals Inc.
  • Second Genome Inc.
  • Seres Therapeutics Inc.
  • Synlogic Inc.
  • Synthetic Biologics Inc.
  • Vithera Pharmaceuticals Inc.
  • Vedanta Biosciences
  • Janssen Research and Development LLC
  • Nestle Health Science S.A.
  • Pfizer Inc.
  • PennCHOP Microbiome Program
  • University of Michigan's Host Microbiome Initiative

For more information about this report visit

View Comments and Join the Discussion!